NYSE:TDOC - Teladoc Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $68.30 +1.25 (+1.86 %) (As of 07/17/2018 04:00 PM ET)Previous Close$67.05Today's Range$67.10 - $69.6052-Week Range$27.30 - $69.60Volume1.89 million shsAverage Volume1.10 million shsMarket Capitalization$4.12 billionP/E Ratio-41.61Dividend YieldN/ABeta0.41 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Teladoc, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. Teladoc, Inc. was founded in 2002 and is headquartered in Purchase, New York. Receive TDOC News and Ratings via Email Sign-up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Offices & clinics of medical doctors Sub-IndustryN/A SectorMedical SymbolNYSE:TDOC CUSIPN/A Webwww.teladoc.com Phone203-635-2002 Debt Debt-to-Equity Ratio0.38 Current Ratio4.15 Quick Ratio4.15 Price-To-Earnings Trailing P/E Ratio-41.61 Forward P/E Ratio-47.43 P/E GrowthN/A Sales & Book Value Annual Sales$233.28 million Price / Sales18.25 Cash FlowN/A Price / CashN/A Book Value$9.80 per share Price / Book6.97 Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-106,780,000.00 Net Margins-41.06% Return on Equity-20.40% Return on Assets-12.48% Miscellaneous Employees1,231 Outstanding Shares62,330,000Market Cap$4,120.34 Teladoc (NYSE:TDOC) Frequently Asked Questions What is Teladoc's stock symbol? Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC." How were Teladoc's earnings last quarter? Teladoc Inc (NYSE:TDOC) announced its quarterly earnings results on Tuesday, May, 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.04. The health services provider had revenue of $89.64 million for the quarter, compared to analyst estimates of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The business's revenue for the quarter was up 109.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.30) EPS. View Teladoc's Earnings History. When is Teladoc's next earnings date? Teladoc is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Teladoc. What guidance has Teladoc issued on next quarter's earnings? Teladoc updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of ($1.41-1.36) for the period, compared to the Thomson Reuters consensus EPS estimate of ($1.35). The company issued revenue guidance of $350-360 million, compared to the consensus revenue estimate of $356.28 million.Teladoc also updated its Q2 guidance to ($0.37-0.35) EPS. What price target have analysts set for TDOC? 18 brokerages have issued 1-year price targets for Teladoc's stock. Their forecasts range from $39.00 to $74.00. On average, they expect Teladoc's share price to reach $54.50 in the next year. This suggests that the stock has a possible downside of 20.2%. View Analyst Ratings for Teladoc. What is the consensus analysts' recommendation for Teladoc? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Teladoc stock? Here are some recent quotes from research analysts about Teladoc stock: 1. Cantor Fitzgerald analysts commented, "4Q17 in line or slightly better than expected. Revenue was $77 million vs. our estimate and FactSet of consensus of $76 million. Visits grew 49%. PMPM was $0.95 vs. $0.91 in 3Q17. Gross margin declined y/y given the expected revenue shift. TDOC reported positive adjusted EBITDA of $2.4M vs FactSet $2.5M. GAAP EPS included several non-recurring/non-cash items. Overall, we believe that TDOC had a strong quarter." (2/27/2018) 2. According to Zacks Investment Research, "The stock of Teladoc has outperformed the industry year to date. The company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2017. The company has incurred significant losses in each period since its inception in 2002. Teladoc has been unable to generate cash from operations and we have doubts over its ability to do so in the coming quarters. Its high debt level has caused a spike in interest expense which has dented its operating margins." (10/18/2017) Who are some of Teladoc's key competitors? Some companies that are related to Teladoc include Cardinal Health (CAH), Smith & Nephew (SNN), UCB S A/ADR (UCBJY), Quest Diagnostics (DGX), ResMed (RMD), UCB (UCBJF), Incyte (INCY), GRIFOLS S A/S (GRFS), IPSEN S A/S (IPSEY), H. Lundbeck A/S- (HLUYY), OLYMPUS Corp/S (OCPNY), Novozymes A/S (NVZMF), Merck KGaA (MKGAF), GENMAB A/S/S (GMXAY) and Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC). Who are Teladoc's key executives? Teladoc's management team includes the folowing people: Mr. Jason Gorevic, CEO & Director (Age 46)Mr. Peter A. McClennen, Pres (Age 49)Mr. Mark J. Hirschhorn, Chief Financial Officer, Chief Operating Officer and Exec. VP (Age 53)Mr. Adam C. Vandervoort, Chief Legal Officer and Sec. (Age 43)Mr. Michael King, Chief Sales Officer (Age 55) When did Teladoc IPO? (TDOC) raised $112 million in an initial public offering on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. Has Teladoc been receiving favorable news coverage? Press coverage about TDOC stock has trended positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Teladoc earned a media sentiment score of 0.32 on Accern's scale. They also gave headlines about the health services provider an impact score of 45.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are Teladoc's major shareholders? Teladoc's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.40%), Summit Partners L P (1.04%), Baillie Gifford & Co. (0.98%), Peregrine Capital Management LLC (0.60%), Handelsbanken Fonder AB (0.07%) and Daiwa SB Investments Ltd. (0.06%). Company insiders that own Teladoc stock include Adam C Vandervoort, Andrew Turitz, James K Outland, Jason N Gorevic, Lp Chp III, Mark Hirschhorn, Michael Goldstein, Michael H King, Peter A Mcclennen and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc. Which major investors are selling Teladoc stock? TDOC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Riverbridge Partners LLC. Company insiders that have sold Teladoc company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Mark Hirschhorn, Michael Goldstein and Peter A Mcclennen. View Insider Buying and Selling for Teladoc. Which major investors are buying Teladoc stock? TDOC stock was purchased by a variety of institutional investors in the last quarter, including Summit Partners L P, Baillie Gifford & Co., Handelsbanken Fonder AB, Calamos Advisors LLC and Daiwa SB Investments Ltd.. View Insider Buying and Selling for Teladoc. How do I buy shares of Teladoc? Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Teladoc's stock price today? One share of TDOC stock can currently be purchased for approximately $68.30. How big of a company is Teladoc? Teladoc has a market capitalization of $4.12 billion and generates $233.28 million in revenue each year. The health services provider earns $-106,780,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Teladoc employs 1,231 workers across the globe. How can I contact Teladoc? Teladoc's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected] MarketBeat Community Rating for Teladoc (NYSE TDOC)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 360 (Vote Outperform)Underperform Votes: 188 (Vote Underperform)Total Votes: 548MarketBeat's community ratings are surveys of what our community members think about Teladoc and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?